United Kingdom (UK)
Recombinant monoclonal antibody to NA, Neuraminidase. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma NA-73.
UniProt Accession Number of Target Protein: S5MF06
Alternative Name(s) of Target: EC:3.2.1.18
Immunogen: The original antibody was raised by taking B cells from influenza A survivors and vaccinees and immortalizing these.
Specificity: This antibody is specific for the rim of the active site of neuraminidase from influenza A.
Application Notes: The structure of the original version of this antibody was determined using cryo-EM and x-ray crystallography (Zhu et al., 2020; PMID:31757767) (Gilchuk et al., 2019; PMID:31757769). This antibody was used for an ELISA on the NA protein of influenza A (Gilchuk et al., 2019; PMID:31757769). The binding strength of this antibody to neuraminidase of influenza A was determined using surface plasmon resonance. This antibody was used for an egress inhibition assay on MDCK cells infected with influenza A. Here it showed its ability to inhibit egress at low concentrations (Gilchuk et al., 2019; PMID:31757769). This antibody was used for a HDX-MS study. The N9 antigen showed hydrogen-deuterium exchange in the presence of this antibody (Gilchuk et al., 2019; PMID:31757769). This antibody was used for a fetuin-based ELLA NA activity assay. Here it showed inhibition of NA (Zhu et al., 2020; PMID:31757767).
Antibody first published in:
Gilchuk et al. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8 PMID:31757769
Note on publication:
The original paper isolated 35 human monoclonal antibodies (mAbs) from two H7N9 survivors and two vaccinees.